Phase 3 Clinical Trials With Primary Completion Dates in July 2026
This is a list of Phase 3 trials with primary completion dates in July 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ANIP | ANI Pharmaceuticals, Inc. | 2026-07-01 | Phase 3 | NCT05486468 | The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment |
| DFTX | Definium Therapeutics, Inc. | 2026-07-01 | Phase 3 | NCT06741228 | A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) |
| HRMY | Harmony Biosciences Holdings, Inc. | 2026-07-01 | Phase 3 | NCT06366464 | A Study of Pitolisant in Patients With Prader-Willi Syndrome |
| LXRX | Lexicon Pharmaceuticals, Inc. | 2026-07-01 | Phase 3 | NCT06481891 | A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy |
| PHVS | Pharvaris N.V. | 2026-07-01 | Phase 3 | NCT05834777 | Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor |
| RARE | Ultragenyx Pharmaceutical Inc. | 2026-07-01 | Phase 3 | NCT06617429 | Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) |
| SNGX | Soligenix, Inc. | 2026-07-01 | Phase 3 | NCT06470451 | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL |